about-us.png

About Us

 

Transforming drug discovery

The Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium is a public-private partnership with the mission of transforming drug discovery by accelerating the development of more effective therapies for patients.

 
transforming-drug-discovery.jpg
 
Congress.png
 

History

In June 2016, GSK, the Department of Energy, and the National Cancer Institute announced their intent to create the ATOM partnership as one of the Cancer Moonshot task forces, with funding support under the 21st Century Cures Act.

The ATOM consortium was officially established in October 2017.

ATOM founding members are GSK, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. 

 

Vision

Our goal is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and patient-centric model. We are integrating high performance computing, diverse biological data, and emerging biotechnologies to create a new pre-competitive platform for drug discovery.

 
 
vision.jpg
The goals of ATOM are tightly aligned with those of the 21st Century Cures Act, which aims in part to enable a greater number of therapies to reach more patients more quickly.
— David Heimbrook, Former Laboratory Director at FNLCR
what-we-do.png

What we do

 

ATOM develops, tests, and validates a multidisciplinary approach to drug discovery in which modern science, technology and engineering, supercomputing simulations, data science, and artificial intelligence are highly integrated into a single drug-discovery team approach that can ultimately be shared with the drug discovery community at large and applied to other disease areas.

The consortium will achieve its goals by building new tools, models, and processes that it intends to make broadly available as a shared resource to accelerate drug discovery. Scientific understanding and vast amounts of data gathered from decades of research will be used by the consortium in hopes that the information will be leveraged to find solutions for cancer patients. 

The ATOM team will combine publicly available data, the data provided by GSK, and that of future consortium members, to generate new dynamic models that can better predict how molecules will behave in the body, potentially bringing new drugs to patients faster. In this effort, Lawrence Livermore National Laboratory will contribute its best-in-class supercomputers, including its next-generation system Sierra, as well as its expertise and innovative approaches to modeling and simulation, cognitive computing, machine learning, and algorithm development. 

 
ATOM transforming drug discovery.png
 
ATOM is a novel public-private partnership that draws on the lab’s unique capabilities to create a paradigm change in drug development
— Bill Goldstein, Director of LLNL
leadership.png

Leadership

 

Joint Research Committee (JRC) & Leadership Team

Jim Brase.jpg

Jim Brase, M.S.

ATOM Chief Technical Officer & Interim Co-Lead / Deputy Associate Director for Computation / Lawrence Livermore National Laboratory
 

Stacie Calad-Thomson.jpg

Stacie Calad-Thomson, Ph.D.

ATOM Chief Operating Officer & Interim Co-Lead

Tom Rush 2.jpg

Tom Rush, Ph.D.

ATOM Chief Scientific Officer & Interim Co-Lead / Senior Director and Head of Biology Automation / GSK

Michelle Arkin.jpg

Michelle Arkin, Ph.D.

ATOM JRC Member / Associate Professor, Department of Pharmaceutical Chemistry / UCSF

Amy Gryshuk.jpg

Amy Gryshuk, Ph.D.

ATOM Deputy Operating Officer / Director, Strategic Engagements, Physical & Life Sciences Directorate / Lawrence Livermore National Laboratory

Dwight Nissley.png

Dwight Nissley, Ph.D.

ATOM JRC Member / Director, Cancer Research Technology Program / Frederick National Laboratory for Cancer Research

Deirdre Olynick.png

Deirdre Olynick, Ph.D.

ATOM Director, Business Development and Operations

 
 

Governing Board

John Baldoni.jpg

John Baldoni, Ph.D.

ATOM Founder and Governing Board Co-Chair / Senior Vice President for R&D / GSK

John MacWilliams.jpg

John MacWilliams, J.D., M.S.

ATOM Governing Board Co-Chair / Senior Advisor to the Director / Lawrence Livermore National Laboratory
 

Alan Ashworth.jpg

Alan Ashworth, Ph.D., F.R.S.

President / UCSF Helen Diller Family Comprehensive Cancer Center

Ethan Dmitrovsky 2.jpg

Ethan Dmitrovsky, M.D.

Laboratory Director / Frederick National Laboratory for Cancer Research

Patricia Falcone 3.jpg

Patricia Falcone, Ph.D.

Deputy Director for Science and Technology / Lawrence Livermore National Laboratory

Jason Paragas 2.jpg

Jason Paragas, Ph.D.

Director, Innovation / Lawrence Livermore National Laboratory

Barry Selick.png

Barry Selick, Ph.D.

Vice Chancellor, Business Development, Innovation, and Partnerships / UCSF

Eric Stahlberg.png

Eric Stahlberg, Ph.D.

Director, High Performance Computing / Frederick National Laboratory for Cancer Research

We need to get better medicines to patients faster. This project aims to do that.
— Alan Ashworth, President of UCSF Helen Diller Family Comprehensive Cancer Center
membership.png

Membership

 
 

Benefits of Membership

ATOM is actively seeking additional partnerships with organizations who share in our vision. Member benefits include access to:


1.    Algorithms and generated data for a member-benefit period
2.    Training and capability development for employees
3.    Best-in-class computational resources
4.    Expertise of the group and leaders in their industries
5.    Unique collaboration and incubation environment
6.    Workflow for internal drug discovery and commercialization

 
 

Consortium Members

GSK logo.jpg

GSK will provide chemical and in vitro biological data for more than 2 million compounds from its historic and current screening collection, as well as preclinical and clinical information on 500 molecules that have failed in development but provide data that could help advance new, successful compounds. GSK also expects to offer expertise in drug discovery and development, computational chemistry, and biology.

llnl simple logo.png

Lawrence Livermore National Laboratory will contribute its best-in-class supercomputers, including its next-generation system Sierra, as well as its expertise and innovative approaches to modeling and simulation, cognitive computing, machine learning, and algorithm development. More broadly, by applying high-performance computing to the ambitious problem of cancer therapy, the Department of Energy and National Nuclear Security Administration hopes to accelerate technologies vital to its core missions.

 
fnlcr_nci-subtext_4line-2.jpg

Frederick National Laboratory, on behalf of the National Cancer Institute, will contribute scientific expertise in precision oncology, computational chemistry and cancer biology, as well as support for open sharing of data sets and predictive modeling and simulation tools. 

UCSF full logo.png

UC San Francisco will provide expertise from a long-history of innovation in medicine and drug discovery combined with its strengths in cancer and translation of technologies and therapeutics to improve the lives of patients.

UCSF scientists and clinicians have long been leaders in drug discovery, therapeutics, and cancer biology with the UCSF Helen Diller Family Comprehensive Care Center among the top-ranked cancer institutes in the country. Our role with ATOM is therefore in lock step with UCSF’s mission of advancing health worldwide.
— Sam Hawgood, MBBS, UCSF Chancellor
contact.png

Contact

 

The ATOM Consortium is actively seeking additional partnerships with qualified pharma, biotech, technology, academic, government, and other organizations.

 
 
 

Headquarters

499 Illinois Street
4th floor
San Francisco,
CA 94158

info@atomscience.org

Connect with us

If you would like to learn more about ATOM, contact us using the link below and one of our team members will get back to you.

We must do all that we can to reduce the time it takes to get medicines to patients. GSK is working to set a precedent with pharmaceutical companies by sharing data on failed compounds.
— John Baldoni, Senior Vice President R&D at GSK
job-opportunities.png

Job Opportunities

 

Check back soon!

 
atom-in-the-news.png

ATOM in the News

 
 

Events

April 3, 2018

Stacie Calad-Thomson, COO presenting at CI4CC Spring 2018 Symposium and Workshop

 

April 5, 2018

ATOM co-hosting the 6th DeepChem User Group Meetup

 

April 17, 2018

Learn How to Partner with ATOM at the ATOM Information Session at the AACR Annual Meeting 2018

 

Media Contacts

Laura Kurtzman

Senior Public Information Officer
UCSF



415-476-3163
laura.kurtzman@ucsf.edu

Jeremy Thomas

Public Information Officer
Lawrence Livermore National Laboratory


925-423-7602
925-422-5539

Frank Blanchard

Director, Public Affairs and Communications
Frederick National Laboratory for Cancer Research

301-846-1893
frank.blanchard@nih.gov

Mary Anne Rhyne

Director, Corporate Communications
GSK



919-483-0492
mary.a.rhyne@gsk.com